Psychedelics Nirvana Life Sciences boasts new patent for innovative psychedelic compound Company isolates 4-PO-Psilocin into biologically active salt with 99% purity ratio Rowan DunneJune 23, 2022
Business Numinus completes Novamind acquisition, upgrades leadership team Novamind's clinics in Utah and Arizona will continue to operate as their current brand until later this year Natalia Buendia CalvilloJune 14, 2022
Business Numinus to enter US psychedelics market via $26.2M Novamind acquisition The transaction is expected to close around June Natalia Buendia CalvilloApril 12, 2022
Business Numinus gets new biosecurity licence to expand psilocybin research CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy Nick LabaMarch 14, 2022
News Psilocybin therapy for major depression can relieve symptoms for a year: study The long-term benefits contrast with the more temporary effects of conventional antidepressants Natalia Buendia CalvilloFebruary 18, 2022
Business Numinus ups revenue 61% thanks to psychedelic-focused therapy programs Expenses were down 71% but the firm still reported a $5.4-million loss Natalia Buendia CalvilloJanuary 21, 2022
Psychedelics Palliative care providers see psychedelic-assisted therapy as treatment option for existential distress: study Currently treatments are largely insufficient, so care providers encourage more research despite stigma Natalia Buendia CalvilloDecember 30, 2021
Business Numinus ends fiscal year with revenue up 72% to $1.5M, losses of $19M The psychedelics firm has been aggressively expanding lab space while pushing ahead with clinical trials Natalia Buendia CalvilloDecember 10, 2021
Business Field Trip Health opens clinic in Vancouver: Q&A with founder Ronan Levy The new facility will feature the firm's ketamine-assisted therapy program, as well as a range of health and lifestyle services Nick LabaDecember 8, 2021
Medical and Pharmaceutical Psilocybin treats depression as well as common antidepressant: study The first head-to-head clinical trial pushes the psychedelic compound closer to becoming a licensed medicine Jared GnamApril 15, 2021